Schedule 13D ownership disclosure
Monte Rosa Therapeutics Inc
Common Stock, par value $0.0001 per share · CUSIP: 61225M102
Event date: 2026-01-07
Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.
- Filing-level shares
- Unavailable
- Percent of class
- Unavailable
- Versant Venture Capital VI, L.P.Reported CIK 0001687880
Shares: 2,236,708 · Class: 3.4%
- Versant Ventures VI GP, L.P.Reported CIK 0001777654
Shares: 2,236,708 · Class: 3.4%
- Versant Ventures VI GP-GP, LLCReported CIK 0001777652
Shares: 2,236,708 · Class: 3.4%
- Versant Vantage I, L.P.
Shares: 1,013,361 · Class: 1.6%
- Versant Vantage I GP, L.P.
Shares: 1,013,361 · Class: 1.6%
- Versant Vantage I GP-GP, LLC
Shares: 1,013,361 · Class: 1.6%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0001193125-26-008951
- Form type
- SCHEDULE 13D/A
- Filer
- Monte Rosa Therapeutics, Inc.
- CIK
- CIK 1826457
- Filed
- Jan 09, 2026
- Reporting period
- Jan 07, 2026
- Description
- Schedule 13D beneficial ownership